Organization (Nonprofit)
Institute for Neurodegenerative Disorders
ClinicalTrials.gov lists Institute for Neurodegenerative Disorders as lead sponsor of 41 trials. It has 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 2 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Institute for Neurodegenerative Disorders: 41 lead-sponsored trials and 1 legal-entity registration.
Disease areas (21)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Parkinson Disease | 30 |
| Dementia | 24 |
| Alzheimer Disease | 23 |
| Disease | 7 |
| Multiple Sclerosis | 4 |
Showing 5 of 21 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2012 | 1 |
| 2011 | 3 |
| 2010 | 4 |
| 2009 | 7 |
Showing 10 of 19 years.
Recruitment duration, a model prediction: none of the 41 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| [18F]Florbetapir PET imaging | 1 |
| Mirapex | 1 |
| Levodopa | 1 |
| Cabergoline | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 2 hit target (n=2) | 50% on time (n=6) |
Journals published in (71)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Neurology | 28 |
| Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 13 |
| Annals of neurology | 8 |
| Journal of neurology, neurosurgery, and psychiatry | 7 |
| Movement disorders : official journal of the Movement Disorder Society | 7 |
Showing 5 of 71 journals.
Organization relationships (7)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 8 |
| Michael J. Fox Foundation | Co sponsors trial with | 3 |
| XingImaging, LLC | Co sponsors trial with | 2 |
| MODAG GmbH | Co sponsors trial with | 2 |
| Alzheimer's Association | Co sponsors trial with | 1 |
Showing 5 of 7 relationships.
Latest dated events (52)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-05-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-05-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2021-08-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2020-07-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 52 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| INSTITUTE FOR NEURODEGENERATIVE DISORDERS | Certificate of waiver | Active |
Biomarker capability evidence (30)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CBS | Trial collaborator | Named in trial inclusion criteria |
| CIT | Trial sponsor | Named in trial inclusion criteria |
| GBA1 | Trial collaborator | Named in trial inclusion criteria |
| GBA1 | Trial collaborator | Named in trial inclusion criteria |
| LRRK2 | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 30 evidence rows.
Biomarkers this organization publishes on (33)
Shown in this order: most publications first.
Showing 5 of 33 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, and workforce and board diversity, as filed.